Perrigo Drug's Pricing Way Off, Expert Says In $163M Tax Trial

By Aebra Coe · June 7, 2021, 7:55 PM EDT

The $466 million an Israeli subsidiary of Irish drugmaker Perrigo Co. earned from sales of a heartburn medication "in no way can possibly comply" with transfer pricing law, an economist said Monday during the...

To view the full article, register now.